Newsroom | 44478 results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived f...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30pm ET/1:30pm PT. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website and will...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update. “Immunome continued to build momentum in the first quarter of 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We remain on track to share topline data for the RINGSIDE trial of varegacestat in the s...

ミネアポリス--(BUSINESS WIRE)--（ビジネスワイヤ） -- 「Edison®（エジソン）ヒストトリプシー・システム」の開発元であるヒストソニックスは、ミシガン州ブルークロス・ブルーシールド（BCBSM）およびブルー・ケア・ネットワークが肝臓のヒストトリプシーに関する新たな医療方針を作成したことを発表しました。この医療保険は、原発性肝腫瘍および転移性肝腫瘍の治療においてエジソン・ヒストトリプシー・システムを用いる非熱的ヒストトリプシーに対応しています。 2025年2月1日時点で、ヒストトリプシーはCPTコード0686Tの下、肝腫瘍を機械による非侵襲的な方法で破壊する治療法として保険償還の対象となり、ミシガン州の適格患者は、2025年7月1日から施行される広範な政策に先立ち、非侵襲的で切開を伴わない、この画期的な治療法をいち早く利用できるようになりました。 ヒストソニックスの社長兼最高経営責任者であるマイク・ブルーは、「肝腫瘍は深刻な癌患者にとって主要な死因であることが多いため、患者に安全で効果的かつ非侵襲的な治療法を提供することは極めて重要です」と述べて、「我々は、BC...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards our long-term goal of developing and ultimately commercializing new innovative medicines for millions of patients. We...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. In connection with the earnings release, Gossamer’s management team will host a l...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2025. “Throughout the fiscal second quarter, Enanta remained squarely focused on executing across our virology and immunology pipeline. We are thrilled to have enrolled our target of 180 patients in RSVHR, a Ph...

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS POSTPONES FIRST QUARTER 2025 CONFERENCE CALL TO LATER THE SAME DAY...

MINNEAPOLIS, Minnesota, USA--(BUSINESS WIRE)--Wie HistoSonics, der Entwickler des Edison Histotripsy System, heute mitteilte, haben Blue Cross Blue Shield of Michigan (BCBSM) und Blue Care Network eine neue Versicherungsrichtlinie für die Histotripsie der Leber erstellt. Mit diesem Schritt wird die Kostenübernahme für die nicht-thermische Histotripsie mit dem Edison® Histotripsy System zur Behandlung von primären und metastasierten Lebertumoren ermöglicht. Seit dem 1. Februar 2025 ist die Histo...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, lo sviluppatore del sistema di istotripsia Edison, ha annunciato oggi che Blue Cross Blue Shield of Michigan (BCBSM) e Blue Care Network hanno istituito una nuova polizza medica che copre l'istotripsia del fegato. La polizza copre l'istotripsia non termica effettuata con il sistema Edison® per il trattamento di tumori epatici primari e metastatici. Dal 1° febbraio 2025, l'istotripsia è una procedura rimborsabile con codice CPT 0686T per la distruzione...